Crispr Therapeutics (CRSP) Cut to “Hold” at BidaskClub
Crispr Therapeutics (NASDAQ:CRSP) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.
A number of other research analysts also recently commented on the stock. SunTrust Banks reaffirmed a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Barclays reaffirmed a “buy” rating and issued a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $22.38.
Crispr Therapeutics (NASDAQ CRSP) traded up $0.13 during midday trading on Friday, hitting $19.12. 324,661 shares of the company were exchanged, compared to its average volume of 260,319. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $25.00.
In related news, CEO Rodger Novak sold 18,470 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $20.76, for a total transaction of $383,437.20. Following the completion of the sale, the chief executive officer now owns 1,148,007 shares in the company, valued at approximately $23,832,625.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Thomas Woiwode sold 1,700 shares of the stock in a transaction on Friday, November 24th. The stock was sold at an average price of $20.21, for a total transaction of $34,357.00. Following the sale, the director now owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,370 shares of company stock valued at $421,842. 39.98% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of CRSP. Credit Suisse AG acquired a new stake in Crispr Therapeutics during the 1st quarter worth $1,742,000. Wells Fargo & Company MN boosted its stake in Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares during the period. Vanguard Group Inc. acquired a new stake in Crispr Therapeutics during the 2nd quarter worth $273,000. Ark Investment Management LLC acquired a new stake in Crispr Therapeutics during the 2nd quarter worth $206,000. Finally, Moloney Securities Asset Management LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth $235,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Crispr Therapeutics (CRSP) Cut to “Hold” at BidaskClub” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/crispr-therapeutics-crsp-cut-to-hold-at-bidaskclub.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related stocks with our FREE daily email newsletter.